Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages

Inflammation Research

Volumn 62, Issue 7, 2013, Pages 711-720

  Salminen, Aino ^a,b   Pussinen, Pirkko J ^a   Payne, Jeffrey B ^c   Stoner, Julie A ^d   Jauhiainen, Matti ^e   Golub, Lorne M ^f   Lee, Hsi Ming ^f   Thompson, David M ^d   Sorsa, Timo ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e BIOMEDICUM HELSINKI   (Finland)

^f STONY BROOK UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Clinical trials; Inflammation; Lipids; Macrophages

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; C REACTIVE PROTEIN; DOXYCYCLINE; GELATINASE B; LOW DENSITY LIPOPROTEIN; NEUTROPHIL COLLAGENASE; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE REGIMEN; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; OSTEOPENIA; PERIODONTITIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; ANTI-BACTERIAL AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; CELLS, CULTURED; CHOLESTEROL; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MACROPHAGES; MIDDLE AGED; PERIODONTITIS; POSTMENOPAUSE; SERUM AMYLOID A PROTEIN;

EID: 84879219355     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0626-z     Document Type: Article

References (33)

1. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012;91:914-20. doi: 10.1177/0022034512457373.
2. Lockhart PB, Bolger AF, Papapanou PN, Osinbowale O, Trevisan M, Levison ME, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation. 2012;125:2520-44. doi: 10.1161/CIR.0b013e31825719f3.
3. Loos BG, Craandijk J, Hoek FJ, Werteim-van Dillen PM, van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol. 2000;71:1528-34. doi: 10.1902/jop.2000.71.10.1528.
4. Joshipura KJ, Wand HC, Merchant AT, Rimm EB. Periodontal disease and biomarkers related to cardiovascular disease. J Dent Res. 2004;83:151-5. doi: 10.1177/154405910408300213.
5. Marcaccini AM, Novaes AB Jr, Meschiari CA, Souza SL, Palioto DB, Sorgi CA, Faccioli LH, Tanus-Santos JE, Gerlach RF. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy. Clin Chim Acta. 2009;409:117-22. doi: 10.1016/j.cca.2009.09.012.
6. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost. 2006;95:511-8. doi: 10.1160/TH05-08-0571.
7. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000. doi: 10.1001/jama.2009.1619.
8. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J Lipid Res. 2003;44:1728-36. doi: 10.1194/jlr.M300100-JLR200.
9. Pussinen PJ, Jauhiainen M, Vilkuna-Rautiainen T, Sundvall J, Vesanen M, Mattila K, Palosuo T, Alfthan G, Asikainen S. Periodontitis decreases the antiatherogenic potency of high density lipoprotein. J Lipid Res. 2004;45:139-47. doi: 10.1194/jlr.M300250-JLR200.
10. Golub LM, Lee H, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26. doi: 10.1177/08959374980120010501.
11. Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy NS, Gruber B, Salo T, Konttinen YT. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol. 1995;22:100-9.
12. Golub LM, Lee HM, Stoner JA, Sorsa T, Reinhardt RA, Wolff MS, Ryan ME, Nummikoski PV, Payne JB. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol. 2008;79:1409-18. doi: 10.1902/jop.2008.070623.
13. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum. 2006;54:621-7. doi: 10.1002/art.21620.
14. Reddy MS, Geurs NC, Cunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol. 2003;8:12-37. doi: 10.1902/annals.2003.8.1.12.
15. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee H, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol. 2004;24:733-8. doi: 10.1161/01.ATV.0000121571. 78696.dc.
16. Tüter G, Kurtiş B, Serdar M, Aykan T, Okyay K, Yücel A, Toyman U, Cemri M, Cengel A, Walker SG, Golub LM. Effects of scaling and root planing and sub-antimicrobial dose doxycycline on oral and systemic biomarkers of disease in patients with both chronic periodontitis and coronary artery disease. J Clin Periodontol. 2007;34:673-81. doi: 10.1111/j.1600-051X.2007. 01104.x.
17. Payne JB, Golub LM, Stoner JA, Lee HM, Reinhardt RA, Sorsa T, Slepian MJ. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc. 2011;142:262-73.
18. Payne JB, Stoner JA, Nummikoski PV, Reinhardt RA, Goren AD, Wolff MS, Lee HM, Lynch JC, Valente R, Golub LM. Subantimicrobial dose doxycycline effects on alveolar bone loss in post-menopausal women. J Clin Periodontol. 2007;34:776-87. doi: 10.1111/j.1600-051X.2007.01115.x.
19. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-53.
20. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979;76:333-7.
21. Pussinen P, Jauhiainen M, Metso J, Tyynelä J, Ehnholm C. Pig plasma phospholipid transfer protein facilitates HDL interconversion. J Lipid Res. 1995;36:975-85.
22. Siggins S, Jauhiainen M, Olkkonen VM, Tenhunen J, Ehnholm C. PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J Lipid Res. 2003;44:1698-704. doi: 10.1194/jlr.M300059-JLR200.
23. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22. doi: 10.1093/biomet/73.1.13.
24. Ohashi R, Mu H, Wang X, Yao Q, Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM. 2005;98:845-56. doi: 10.1093/qjmed/hci136.
25. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801. doi: 10.1161/ATVBAHA.109.199158.
26. Jung K, Lein M. By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results. J Clin Periodontol. 2009;36:34-5. doi: 10.1111/j.1600-051X.2008.01336.x.
27. Kuvaja P, Talvensaari-Mattila A, Turpeenniemi-Hujanen T. The sample type used affects the levels of gelatinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in circulating blood of healthy controls and breast cancer patients. Biomark Insights. 2007;2:117-27.
28. Tuomainen AM, Nyyssönen K, Tervahartiala T, Sorsa T, Pussinen PJ. Letters to the Editor, response: matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. Arterioscler Thromb Vasc Biol. 2008;28:e17. doi: 10.1161/ATVBAHA.107. 159277.
29. Tuomainen AM, Nyyssönen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT, Sorsa T, Pussinen PJ. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol. 2007;27:2722-8. doi: 10.1161/ATVBAHA.107.154831.
30. Tuomainen AM, Kormi I, Havulinna AS, Tervahartiala T, Salomaa V, Sorsa T, Pussinen PJ. Serum tissue-degrading proteinases and incident cardiovascular disease events. Eur J Prev Cardiol. 2012 Oct 18. [Epub ahead of print]. doi: 10.1177/2047487312465524.
31. Moutsopoulos NM, Madianos PN. Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann N Y Acad Sci. 2006;1088:251-64. doi: 10.1196/annals.1366.032.
32. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkilä E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 1988;37:859-65. doi: 10.1016/0026-0495(88)90120-5.
33. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2910-3. doi: 10.1161/01.ATV.17.11.2910.